The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer
- 1 May 2017
- journal article
- Published by Elsevier in European Urology
- Vol. 71 (5) , 748-749
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at DeathEuropean Urology, 2017
- DNA Repair in Prostate Cancer: Biology and Clinical ImplicationsEuropean Urology, 2017
- Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectoriesNature Communications, 2017
- Genomic hallmarks of localized, non-indolent prostate cancerNature, 2017
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerNew England Journal of Medicine, 2016
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor PrognosisEuropean Urology, 2015
- Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate CancerJournal of Clinical Oncology, 2013